Brofaromine (Consonar) is a reversible inhibitor of monoamine oxidase A discovered by Ciba-Geigy. The drug is primarily useful in the treatment of depression and anxiety. Brofaromine also has serotonin reuptake inhibitory properties and its dual pharmacologic effects offer promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with standard drugs although it is not commercially available and is not being actively researched, possibly due to a lack of financial interest.

Brofaromine is a reversible inhibitor of monoamine oxidase A (RIMA, a type of monoamine oxidase inhibitor (MAOI)) and acts on epinephrine (adrenaline), norepinephrine (noradrenaline), serotonin, and dopamine. Unlike standard MAOIs, possible side effects do not include cardiovascular complications (hypertension) with encephalopathy, liver toxicity or hyperthermia.






This page contains text from Wikipedia, the Free Encyclopedia - http://en.wikipedia.org/wiki/Brofaromine

This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.